TG Therapeutics is executing strongly on the commercial launch of Briumvi, with revenue accelerating 87.3% year-over-year to $616M TTM and sequential growth of 70.3% in 2026Q2. However, investors should monitor gross margin erosion (down 840bps to 82.9% since 2024Q1) and the company's reliance on a single product.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue surged 87.3% year-over-year to $616M TTM, with sequential growth accelerating to 70.3% in 2026Q2, but gross margin contracted 840bps to 82.9% from 2024Q1, indicating pricing pressure.
Comprehensive stock analysis, price targets, and earnings estimates are readily available for informed investment decisions.
Real-time stock price, charts, and key statistics provide up-to-date information for investors.
Regular news updates and headlines keep investors informed about the latest developments.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 3, 2026 | $0.05-83.6% vs $0.31 | $240M+4.6% vs $230M |
Q2 2026 May 6, 2026 | $0.14-39.1% vs $0.23 | $205M+2.3% vs $200M |
Q1 2026 Feb 26, 2026 | $0.14-60.0% vs $0.35 | $193M+0.4% vs $192M |
Q4 2025 Nov 3, 2025 | $2.43+912.5% vs $0.24 | $162M-16.6% vs $194M |
Four biotech stocks, including TG Therapeutics and Immunome, show positive Earnings ESPs and favorable Zacks Ranks, positioning them for potential third-quarter earnings beats.
NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, November 9, 2026, at 8:30 AM ET to discuss results for the third quarter 2026 and to provide a business outlook for the remainder of 2026. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnin.
GRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health partnerships and growing clinical evidence of cancer detection.
TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Benchmark TGTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for TG Therapeutics, Inc. (TGTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $59.83 | $9.16B | 21.31 | 87.32% | 55.22% | 72.3% | — | |
| $18.28 | $2.3B | -5.23 | -4.26% | -445% | -90.04% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $277.62 | $7.74B | -23.85 | -100% | — | -34.15% | — | |
| $131.73 | $10.84B | -37.73 | -16.72% | -341.87% | -22.39% | — | |
| $547.09 | $138.85B | 35.12 | 9.57% | 30.61% | 20.08% | — |
TG Therapeutics, Inc. (TGTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
TG Therapeutics, Inc. (TGTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 3, 2026·SEC
Jun 12, 2026·SEC
Jun 3, 2026·SEC
Get notified when TGTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TG Therapeutics, Inc. (TGTX) stock FAQ — growth, dividends, profitability & financials explained
TG Therapeutics, Inc. (TGTX) reported $799.5M in revenue over the trailing twelve months. Revenue was $616.3M in fiscal year 2025. That is 616187% more than the $0.1M of fiscal year 1996.
TG Therapeutics, Inc. (TGTX) grew revenue by 76.1% over the trailing twelve months, compared with the twelve months before.
Yes. TG Therapeutics, Inc. (TGTX) earned $441.5M in net income over the trailing twelve months (a 55.2% net margin).
TG Therapeutics, Inc. (TGTX) had a return on equity (ROE) of 72.3% over the trailing twelve months. That is well above the market's typical 10-15%.
TG Therapeutics, Inc. (TGTX) generated $17.4M in free cash flow over the trailing twelve months.
